Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2013 pubmed 56 citations

Molecular analysis of non-specific protection against murine malaria induced by BCG vaccination.

Parra. Marcela M; Liu. Xia X; Derrick. Steven C SC; Yang. Amy A; Tian. Jinhua J; Kolibab. Kristopher K; Kumar. Sanjai S; Morris. Sheldon L SL

Key Findings

  • BCG vaccination raises LL‑37 and other antimicrobial peptides in mice
  • LL‑37 (cathelicidin) directly reduces Plasmodium yoelii parasite levels when parasites are pre‑treated
  • BCG‑vaccinated mice show lower malaria parasitemia compared to non‑vaccinated controls

Practical Outcomes

  • While you can’t directly take LL‑37, the findings hint that boosting your own LL‑37 (e.g., via vitamin D or BCG vaccination) might enhance broad antimicrobial defenses. However, human evidence is lacking, so treat this as a mechanistic insight rather than a ready‑to‑use protocol.

Summary

The study shows that a TB vaccine (BCG) can boost the body’s natural antimicrobial peptide LL‑37 in mice, and that LL‑37 can lower malaria parasite levels when the parasites are exposed to it. This suggests LL‑37 has some anti‑malaria activity, but the work is done in mice and involves pre‑treating the parasites, not a practical human treatment yet.

Abstract

Although the effectiveness of BCG vaccination in preventing adult pulmonary tuberculosis (TB) has been highly variable, epidemiologic studies have suggested that BCG provides other general health benefits to vaccinees including reducing the impact of asthma, leprosy, and possibly malaria. To further evaluate whether BCG immunization protects against malarial parasitemia and to define molecular correlates of this non-specific immunity, mice were vaccinated with BCG and then challenged 2 months later with asexual blood stage Plasmodium yoelii 17XNL (PyNL) parasites. Following challenge with PyNL, significant decreases in parasitemia were observed in BCG vaccinated mice relative to naïve controls. To identify immune molecules that may be associated with the BCG-induced protection, gene expression was evaluated by RT-PCR in i) naïve controls, ii) BCG-vaccinated mice, iii) PyNL infected mice and iv) BCG vaccinated/PyNL infected mice at 0, 1, 5, and 9 days after the P. yoelii infection. The expression results showed that i) BCG immunization induces the expression of at least 18 genes including the anti-microbial molecules lactoferrin, eosinophil peroxidase, eosinophil major basic protein and the cathelicidin-related antimicrobial peptide (CRAMP); ii) an active PyNL infection suppresses the expression of important immune response molecules; and iii) the extent of PyNL-induced suppression of specific genes is reduced in BCG-vaccinated/PyNL infected mice. To validate the gene expression data, we demonstrated that pre-treatment of malaria parasites with lactoferrin or the cathelicidin LL-37 peptide decreases the level of PyNL parasitemias in mice. Overall, our study suggests that BCG vaccination induces the expression of non-specific immune molecules including antimicrobial peptides which may provide an overall benefit to vaccinees by limiting infections of unrelated pathogens such as Plasmodium parasites.

Study Information

Provider

pubmed

Year

2013

Date

2013-07-04T00:00:00.000Z

DOI

10.1371/journal.pone.0066115

Citations

56

References

47